Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jihao Zhou

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
American Journal of Cancer Research|April 20, 2026
Rare <i>NUP98::SETBP1</i> fusion transcript in a refractory adult T-cell lymphoblastic lymphomaXiaoyong Chen, Linlin Wang, Junyan Zou, et al.
The Journal of Urology|October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialRoger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
Transplantation Proceedings|July 7, 2024
Incidence, Etiology and Prognosis of Initial Liver Injury After Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Retrospective StudyJingsong Wu, Xiaohan Zhang, Baozhen Qin, et al.
European Urology|April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trialChristopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
European Urology|October 27, 2012
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasiaMichael Marberger, Emmanuel Chartier-Kastler, Blair Egerdie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 21, 2010
Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysisStuart A Yablon, Mitchell F Brin, Amanda M VanDenburgh, et al.
Acta Haematologica|October 10, 2019
Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in ChildrenPeng Ke, Xiebing Bao, Jihao Zhou, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 22, 2009
A new probabilistic rule for drug-dug interaction predictionJihao Zhou, Zhaohui Qin, Sara K Quinney, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
American Journal of Cancer Research|April 20, 2026
Rare <i>NUP98::SETBP1</i> fusion transcript in a refractory adult T-cell lymphoblastic lymphomaXiaoyong Chen, Linlin Wang, Junyan Zou, et al.
The Journal of Urology|October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialRoger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
Transplantation Proceedings|July 7, 2024
Incidence, Etiology and Prognosis of Initial Liver Injury After Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Retrospective StudyJingsong Wu, Xiaohan Zhang, Baozhen Qin, et al.
European Urology|April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trialChristopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
European Urology|October 27, 2012
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasiaMichael Marberger, Emmanuel Chartier-Kastler, Blair Egerdie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 21, 2010
Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysisStuart A Yablon, Mitchell F Brin, Amanda M VanDenburgh, et al.
Acta Haematologica|October 10, 2019
Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in ChildrenPeng Ke, Xiebing Bao, Jihao Zhou, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 22, 2009
A new probabilistic rule for drug-dug interaction predictionJihao Zhou, Zhaohui Qin, Sara K Quinney, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
Pageof 5